Few of the record 143 biotech startups that made their public debut last year had a product to sell. We unpack the odd nature of biotech IPOs.
A Crunchbase analysis of 17 venture-funded companies from China that went public on Nasdaq and the New York Stock Exchange in the past two years...
Palo Alto, California-based TripActions has confidentially filed to go public next year. The company is aiming for a $12 billion valuation in Q2 of...
Cambridge, Massachusetts-based Third Harmonic Bio joined fellow sector IPOs by Seattle-based Know Labs and Texas-based BioAffinity Technologies.
With the end of the fiscal year in sight, writes Manhattan Venture Partners' Jared Carmel, companies that may have intended to go public earlier this...
Remember IPOs? Those were fun days. As the IPO summer drought drags on, we looked at some of the bountiful seasons for companies going public and...
Currently, virtually every venture-funded company that went public in 2020 or 2021 is trading at a fraction of its former high. The hardest hit have...
At the end of last year–a record year for the IPO market–Crunchbase News published our top predictions for companies that could go public in 2022. ...
The U.S. stock market has officially dipped into bear market territory, largely driven by big declines for tech stocks this year. That dip has caused...
After peaking in 2021, venture funding to biotech startups slowed in 2022, with investment on pace to come in at least a third lower than last year’s...
Chinese regulators are preparing to end a ban on bringing on new users to Didi in a culmination of an investigation into the company’s cybersecurity...
67.1K Followers